N/A Completed N=75 Randomized Treatment

Comparison of Acetaminophen and PRP Therapy for Knee OA

Source: ClinicalTrials.gov NCT01782885 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2015

Primary outcomePrimary: Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC) — 3.0; 2.9; 8.0; 7.4 units on a scale

Summary

The purpose of this study is to test whether the platelet-rich plasma (PRP) intra-articular injection therapy is effective as an alternative treatment option in patients with mild knee osteoarthritis within a controlled randomized study compared to first line treatment acetaminophen. The investigators will evaluate patients outcome in level of pain, knee function and quality of life before the treatment and at 6, 12 and 24 weeks follow up. The study will be complemented with in vitro experiments of human osteoarthritic cartilage explants culture (treated with PRP) for histological and gene expression assays. PRP intra-articular injections therapy is effective in patients with mild knee osteoarthritis by modifying the biochemical joint environment and cartilage regeneration capability.

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC)	1.9; 0.8; 5.3; 2.9; 16.7; 7.9	—
SECONDARY Change in Visual Analog Scale (VAS)	5.9; 4.9; 3.8; 1.9; 4.1; 1.9	—

Eligibility Criteria

Inclusion Criteria

Older than 18 years old
Patients who haven't received steroids injection or medical treatment 1 month before the study
Patients with knee osteoarthritis grade I and II (Kellgren-Lawrence scale)
Indistinct gender
Patients who accept to participate in the study with previous signed informed consent

Exclusion Criteria

Patients with knee osteoarthritis grade III and IV (Kellgren-Lawrence scale)
Patients with prosthesis
Pregnancy
Patients with rheumatic diseases
Patients with diabetes, hepatic diseases, coagulopathy, cardiovascular diseases, immunosuppression, infections
Patients taking anticoagulants
Patients with concentrations of hemoglobin under 11 g/dL and platelets under 150,000/uL

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01782885). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.